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Objectives: Staging data on patients with non–small cell lung cancer were prospec-
tively collected to evaluate the accuracy and anatomic information provided by
fluorodeoxyglucose F 18 positron-emission tomography and its impact on improv-
ing the accuracy of surgical staging.
Methods: A total of 142 patients with potentially resectable non–small cell lung
cancer were imaged with positron-emission tomography (neck to pelvis). Positron-
emission tomographic scans were read prospectively with thoracic computed tomo-
graphic comparison. Patients without distant metastases at positron-emission to-
mography underwent staging with bronchoscopy and mediastinoscopy, with or
without mediastinotomy or thoracoscopy. Patients with metastases, pleural im-
plants, or N2 or N3 disease did not undergo primary resection.
Results: Positron-emission tomography revealed unsuspected distant metastases in
24 of 142 patients (16.9%) and unsuspected pleural implants in 6 others. Nodal stage
was surgically established in 118 cases. Positron-emission tomography showed that
5 patients had nodal disease not accessible by mediastinoscopy. In 35 (24.6%) of
these 142 cases, positron-emission tomography directed the evaluation away from
routine bronchoscopy and mediastinoscopy staging that would have resulted in
inappropriate treatment selection. Positron-emission tomography correctly differen-
tiated resectable stages IA through IIIA (N1) from stages IIIA (N2) through IV in
88.7% of cases. In identifying N2 or N3 disease, positron-emission tomography had
an accuracy of 90.7%, a sensitivity of 80.9%, a specificity of 96%, and positive and
negative predictive values of 91.9% and 90.1%, respectively. Of the 8 cases in
which positron-emission tomography missed N2 disease, 7 had the disease discov-
ered by mediastinoscopy and 1 had it discovered at thoracotomy.
Conclusions: The diagnostic accuracy of positron-emission tomography–enhanced
clinical staging is high. Positron-emission tomography has previously been used
primarily to screen for lymph node spread and distant metastases, but it also
provides localizing information that allows directed and more sensitive surgical
staging and refinement of patient selection for curative resection. Positron-emission
tomography and surgical staging play complementary roles in the journey toward
more accurate overall staging.
Lung cancer remains the leading cause of cancer death in the UnitedStates, with more than 170,000 new patients and 158,000 deaths in1999,1 80% with non–small cell histologic type. Stage of non–smallcell lung cancer (NSCLC) is the most significant factor determiningprognosis, management, and operability. The recently revised TNMstaging system for lung cancer shows a 5-year survival ranging from
1% for stage IV disease to 67% for completely resected stage IA cancers.2 Metic-
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ulous staging of NSCLC is critical to prevent clinical over-
staging and the consequent denial of therapy with curative
intent. Accurate staging is also important to avoid clinical
understaging and the consequent morbidity, time, and cost
associated with ineffective therapies, particularly unneces-
sary thoracotomy. In addition, accurate staging is necessary
for the selection and enrollment of patients in clinical trials.
Therefore every means should be used to establish the
correct stage of a newly diagnosed lung cancer before
initiating therapy.
Clinical staging of NSCLC routinely includes computed
tomography (CT) of the thorax. No additional imaging is
currently recommended to detect metastatic disease in the
absence of clinical or laboratory evidence of distant disease.
CT imaging of the thorax allows localization of the primary
tumor with respect to anatomic structures, providing valu-
able information on the primary tumor (T stage) and its
resectability. CT also provides an important assessment of
mediastinal lymph nodes (N status), although CT alone has
been found to have low sensitivity (64%) and specificity
(62%) for identification of malignant N2 and N3 lymph
nodes.3
Invasive staging, consisting of mediastinoscopy, medi-
astinotomy, thoracoscopy, and ultimately thoracotomy, pro-
vides the ultimate criterion standard for histologic confir-
mation of staging. Most institutions reserve staging by
mediastinotomy, thoracoscopy, and thoracotomy for evalu-
ation of specific abnormalities detected during preoperative
imaging studies. Mediastinoscopy is routinely recom-
mended to confirm or exclude malignancy in enlarged me-
diastinal lymph, nodes in accordance with National Com-
prehensive Cancer Network NSCLC guidelines.4 The utility
of mediastinoscopy in the presence of normal-sized medi-
astinal lymph nodes is more controversial. Even patients
with peripheral T1 tumors and no mediastinal adenopathy
according to CT may be found to have positive mediastinal
lymph nodes in as many as 21% of cases.5 Because N2
disease is a strong marker for probable occult distant met-
astatic disease, many thoracic surgeons routinely perform
mediastinoscopy, which provides the opportunity to con-
sider induction therapy before thoracotomy. Several large
series have now documented the safety of mediastinoscopy,
with a morbidity of 1% to 2% and mortality of 0.05% to
0.1%.6,7 In experienced hands mediastinoscopy is extremely
accurate, with an average sensitivity of 84%, a specificity of
100%, and a false-negative rate averaging 9% in 10 large
series.8-17 Primary surgical resection for the patient with
NSCLC is not usually performed in the presence of medi-
astinal lymph node involvement, malignant pleural im-
plants, or distant metastatic disease.
Clinical staging of NSCLC could benefit from both more
sensitive and more specific detection of distant metastases,
as well as from improved accuracy in mediastinal staging.
In recent years multiple studies have shown that positron-
emission tomography (PET) with fluorodeoxyglucose F 18
(FDG) can fulfill both these goals.18-32 It is now well estab-
lished that FDG PET will detect the presence of unsus-
pected extrathoracic metastases in 14% to 16.5% of patients
with disease otherwise deemed resectable (clinical stage
IIIA or less).18-20 The diagnostic accuracy of FDG PET in
staging the mediastinum has also been reported in multiple
studies.18-31 In a meta-analysis of 14 PET studies and 29 CT
studies, Dwamena and associates32 reported that PET was
significantly more accurate than CT in demonstrating nodal
metastases (P  .001). The mean sensitivity and specificity
were 79%  3% and 91%  2%, respectively, for PET and
60%  2% and 77%  2%, respectively, for CT.
Beyond the identification of unsuspected extrathoracic
distant metastases and provision of noninvasive mediastinal
staging, FDG PET also plays an important role in the
surgical staging of potentially resectable NSCLC disease.
Although the role of FDG PET in staging NSCLC is often
discussed as being mutually exclusive with that of medias-
tinoscopy, the two procedures can play complementary
roles. The impact of FDG PET on the approach to surgical
staging and the interplay between FDG PET and the selec-
tion of mediastinoscopy or other staging procedures has not
been addressed. We reviewed our prospective experience
with FDG PET combined with CT and routine mediastinos-
copy and examined the impact of PET findings on directing
surgical staging procedures and refining staging before tho-
racotomy.
Methods
Potential subjects were all patients referred with a diagnosis of
NSCLC to the thoracic surgery clinics at the University of Wash-
ington Medical Center or the Veterans Affairs Puget Sound Health
Care System between February 1998 and May 2001. All patients
underwent CT imaging of the thorax, and those with potentially
resectable NSCLC were referred for imaging with FDG PET. All
patients were imaged with FDG PET except for patients with
lesions too small (1 cm) or of insufficient cellularity (not visible
on mediastinal windows of CT). These exclusions were intended to
ensure adequate quantitation of FDG uptake in the primary lesion.
Patients in whom the histologic type was subsequently found to be
different from NSCLC or in whom the histologic type could not be
confirmed were excluded. Patients with type I diabetes were also
excluded. None of these patients had received induction therapy
before PET, surgical staging, or resection (except for local brain
therapy in the case of those with an isolated brain metastasis). All
patients had to be operative candidates if the tumor was found to
be stage I or II, or T3 N1 M0. A total of 142 patients satisfied these
enrollment criteria.
Positron-Emission Tomographic Imaging
All PET studies were performed with a dedicated whole-body PET
tomograph (PET Advance; General Electric Medical Systems,
Milwaukee, Wis). Patients were asked to fast for 12 hours before
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tracer administration. Two intravenous catheters were placed in
opposite arms, one for tracer administration and the other for blood
sampling. An initial blood sample was obtained at the time of
intravenous catheter placement to screen for abnormally high
plasma glucose levels. Just before tracer administration, patients
also received 1 mg of lorazepam intravenously to decrease benign
muscular uptake in the neck and upper thorax that could compro-
mise image interpretation. Seven to 11 mCi of FDG were infused
intravenously during 2 minutes with a Harvard pump (Harvard
Apparatus, Inc, Holliston, Mass). After a 45-minute rest period,
patients were placed supine in the scanner with the thorax posi-
tioned to fit within two contiguous 15-cm wide tomograph fields of
view. Imaging always started with a 15-minute emission scan
performed over the thoracic field of view encompassing the pri-
mary lung cancer. This allowed quantitative analysis of tracer
uptake by means of the standard uptake value in the primary tumor
in a standard period (45-60 minutes) after injection, to control for
the time dependence of the standard uptake value. The other
thoracic field of view and the abdomen were also imaged with
10-minute emission scans. Five-minute emission scans were per-
formed over the neck and pelvis. These scans were followed by
15-minute transmission studies over the three fields of view en-
compassing the chest and abdomen, performed after all emission
studies had been completed.
All studies were collected in 2-dimensional imaging mode with
scatter septa in place. Real-time random correction with counts
obtained with a delayed coincidence window and deconvolution-
based scatter corrections supplied by the manufacturer were ap-
plied. The raw PET data were reconstructed with the standard
filtered back projection available on the PET Advance system. The
following reconstruction parameters were used: 12-mm Hanning
filter, 55-cm image diameter, and 128  128 array size. Both
emission scans and attenuation-corrected scans were reconstructed
for each patient. The transmission scan, which is coregistered with
the other two scans, was also reconstructed to provide anatomic
localization details that might not be easily appreciated on the two
other scans. All FDG PET scans were read prospectively on a
dedicated workstation by the same experienced reader (H.V.) and
with the benefit of comparison with the corresponding thoracic CT
scans. The following 5-point scale was used on the attenuation-
corrected images for the evaluation of FDG activity in lymph
nodes: 1, not identifiable on the imaging workstation; 2, lower
activity than mediastinal blood pool activity; 3, equal to minimally
greater than mediastinal blood pool activity; 4, greater than medi-
astinal blood pool activity; and 5, much greater than mediastinal
blood pool activity. Lymph nodes with activity levels 4 and 5 were
read as malignant, with others read as benign.
Surgical Staging
The imaging and surgical evaluations of patients enrolled in this
study are summarized on Figure 1. Patients with stage IV disease
according to FDG PET had metastatic status confirmed by either
additional anatomic imaging or percutaneous biopsy. Patients
without distant metastases at PET but with PET evidence of
pleural implants underwent thoracoscopy for confirmation if find-
ings were not confirmed as pleural nodules on subsequent second
review of the thoracic CT scan. Patients without distant metastases
at PET but with evidence of mediastinal disease in a location that
would not be accessible by mediastinoscopy underwent surgical
staging with thoracoscopy, mediastinotomy, or thoracotomy as
indicated. All other patients underwent staging with bronchoscopy
and mediastinoscopy. Surgical confirmation of the lymph node
status by mediastinoscopy was performed in all patients indepen-
dent of the size of these nodes on chest CT or the presence or
absence of uptake by PET imaging. The results of FDG PET
imaging in the mediastinum were available to the surgeon before
confirmation of the mediastinal nodal status.
Pathologic Examination
All biopsy and resection specimens were reviewed by the pathol-
ogy departments of the University of Washington Medical Center
and the Veterans Affairs Puget Sound Health Care System. The
non–small cell nature of each tumor was confirmed, as was the
histologic subtype. The T and N statuses for each tumor were
assessed.
FDG PET and surgical staging data of these lung cancers were
prospectively collected to evaluate the accuracy and disease local-
izing information provided by PET in planning surgical staging
and to compare PET staging with pathologic staging. The impact
of this information on surgical staging was also examined. This
study was conducted under University of Washington institutional
review board approval.
Results
FDG PET was used to stage the disease of 142 patients with
NSCLC. The histologic type and lesion size distributions
for the patients of this series are as shown in Tables 1 and
2. Of these, 7 patients with a treated solitary brain metas-
tasis were seen for evaluation of resectability of the primary
lung cancer. Additional unsuspected extracranial metastases
(M1) were identified by FDG PET in 3 of these 7 cases. Of
the remaining 135 patients without initial evidence of met-
astatic disease to the brain, 21 (15.5%) of 135 were found to
have metastatic disease by PET. Overall, PET discovered
unsuspected M1 disease in 24 (16.9%) of 142 patients
(including patients with a treated brain lesion), and no
pulmonary resection was performed in these cases. This
unsuspected M1 disease was confirmed by biopsy in 5
cases, by CT in 8 cases, by magnetic resonance imaging in
9 cases, and by bone scan in 2 cases.
Eight cases were clinically staged as T4 lesions by CT
scan. PET confirmed each of these T4 lesions. PET also
found an additional 7 unsuspected cases of T4 disease, 6
with pleural tumor implants. Fourteen of the 15 cases were
confirmed (including the 6 cases of pleural involvement),
and 8 additional cases of T4 disease that had not been
suspected either clinically or by PET were revealed at
pathologic examination. Three were tracheal involvement, 2
were great vessel or myocardium involvement, and 3 were
“satellite” lesions close to but separate from the main lesion.
The nodal status was proved surgically in 118 cases.
Table 3 details the results of the nodal staging by PET
relative to the surgicopathologic N stage. PET correctly
Vesselle et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 3 513
G
TS
staged the absolute N status in 83 of 118 cases (70.3%).
However, FDG PET correctly differentiated N0 or N1 dis-
ease from N2 or N3 disease in 101 (85.6%) of 118 cases
(Table 3). Most important, FDG PET correctly differenti-
ated cases with mediastinal lymph node involvement (N2-
N3) from those without such involvement (N0-N1) in 107
(90.7%) of 118 cases (Table 3). The data in Table 3 show
that for the identification of mediastinal nodal disease, FDG
PET had a sensitivity of 80.9%, a specificity of 96.0%, a
positive predictive value of 91.9%, and a negative predic-
tive value of 90.1%. PET correctly differentiated resectable
stage IA through IIIA (N1) disease from nonresectable stage
IIIA (N2) through IV disease in 126 (88.7%) of 142 cases.
PET correctly identified most N0 disease (n  49/55) but
was less accurate for N1 disease (n  6/21; Table 3).
Figure 1. FDG-PET– based clinical and surgical staging and management of NSCLC.
TABLE 1. Histologic distribution for the reported cases
Histologic type No.
Adenocarcinoma 51
Bronchioloalveolar cell 6
Large cell 10
Squamous cell 38
Other (carcinosarcoma) 2
NSCLC not otherwise specified 35
Total 142
TABLE 2. Primary tumor size distribution for the reported
cases
Tumor greatest diameter (cm) No.
1, 2 22
2, 3 28
3, 4 39
4 53
Total 142
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Of the 118 patients in whom the nodal status was surgi-
cally confirmed, 112 underwent a mediastinoscopy. No
cases of N3 disease were underestimated as N0 or N1 by
PET (Table 3). However, PET underestimated the presence
of N2 nodal disease in 8 (6.8%) of 118 patients. In these 8
cases, PET showed no abnormal uptake in the mediastinum
and therefore provided no localizing information to guide
surgical staging. Mediastinoscopy identified 7 (87.5%) of
the 8 positive N2 lymph nodes that were negative by PET
criteria, and in 1 (12.5%) of the 8 a positive subcarinal
lymph node was missed at mediastinoscopy and discovered
at thoracotomy.
In 5 cases PET identified mediastinal lymph node in-
volvement at unique locations that were neither accessible
to nor identified by the standard surgical staging with bron-
choscopy and mediastinoscopy (2 posterior subcarinal
lymph nodes, 2 aortopulmonary window nodes, and 1 para-
esophageal node). In these cases the involved node was
found either at thoracotomy or thoracoscopy, and no other
mediastinal lymph nodes were involved. If one considers
these 5 cases together with the 6 cases of unsuspected
pleural disease, there were 11 (9.3%) of 118 cases without
unsuspected distant metastases for which the standard ap-
proach of bronchoscopy and mediastinoscopy would have
led to an inaccurate stage.
Discussion
Accurate staging is paramount in assigning the most effec-
tive, most efficient, and least morbid therapy for patients
with NSCLC. PET correctly differentiated resectable stages
IA through IIIA (N1) from nonresectable stages IIIA (N2)
through IV in 126 (88.7%) of 142 cases. FDG PET did not
reliably identify N1 disease, with only 6 of 21 cases iden-
tified. This lack of sensitivity for N1 disease probably stems
from the fact that N1 lymph nodes are usually located close
to the primary tumor, and thus their modest FDG accumu-
lation relative to the more intense uptake of the primary
mass may be difficult to discriminate. In addition, this low
sensitivity for N1 disease may in part result from the small
size of intralobar N1 nodes, which are rarely identified on
chest CT. Nonetheless, FDG PET accurately differentiated
N0 or N1 disease from N2 or N3 disease in 90.7% of cases,
and this is the most important differentiation to be made for
preoperative treatment planning. Patients with N0 or N1
status are preferentially treated by primary resection without
induction therapy, although induction therapy trials for
these patients are underway. In the era predating the avail-
ability of FDG PET, the N1 status of a tumor was in most
instances only discovered on pathologic review of the re-
sected specimen. This situation may be only modestly im-
proved by FDG PET. In current management protocols, a
change from N0 to N1 would not result in a change in
patient management, but it is associated with a decrease in
5-year survival.
The most important finding from this study is that FDG
PET revealed the presence of unsuspected advanced disease
(T4 implants in 6 and M1 disease in 24) in 30 (21.1%) of
142 patients. Among the patients without a known history of
a treated brain metastasis, unsuspected advanced disease
was found in 27 (20%) of 135. In these patients manage-
ment was altered toward confirmation of advanced stage
rather than mediastinal lymph node evaluation, thoracot-
TABLE 3. Lymph node status at FDG-PET versus pathologic examination
By PET
At pathologic examination
N0 N1 N2 N3 Total
N0 49 14 5 0 68
N1 4 6 3 0 13
N2 2 1 22 4 29
N3 0 0 2 6 8
Total 55 21 32 10 118
At pathologic examination
By PET N0-1 N2 N3 Total
N0-1 73 8 0 81
N2 3 22 4 29
N3 0 2 6 8
Total 76 32 10 118
At pathologic examination
By PET N0-1 N2-3 Total
N0-1 73 8 81
N2-3 3 34 37
Total 76 42 118
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omy, and resection as originally planned. In another 5
(4.2%) of 118 cases, FDG PET revealed lymph node disease
at nodal stations that would not have been evaluated by
mediastinoscopy. These nodes could then be targeted in a
specific diagnostic approach to confirm or exclude N2 or N3
nodal disease, preventing primary resection of locally ad-
vanced NSCLC and directing patients toward combined
modality therapy. In the other cases in which uptake on
FDG PET indicated mediastinal lymph node involvement
with tumor, FDG PET provided localizing information used
by the thoracic surgeon to target the lymph nodes of highest
yield. This was especially critical in cases in which the chest
CT did not reveal any evidence of mediastinal lymph node
enlargement.
The addition of FDG PET to the diagnostic workup of
potentially resectable NSCLC patients provides multiple
benefits. The discovery of metastatic disease avoids a non-
therapeutic thoracotomy, with its attendant morbidity and
mortality, permits the referral of these patients for chemo-
therapy, and also avoids inefficient and unnecessary surgi-
cal staging procedures. PET also may help to improve the
accuracy of prethoracotomy mediastinoscopy by identifying
lymph nodes that are suspect for metastasis and can be
specifically targeted for biopsy. Mediastinoscopy is still
useful to confirm the presence of N2 or N3 disease, because
PET overstaged the mediastinal lymph nodes in 3 (2.5%) of
118 patients who might have been incorrectly denied sur-
gery with curative intent. The value of routine mediastinos-
copy is supported, because PET understaged the mediasti-
num in 8 (6.8%) of 118 patients, and 7 (87.5%) of 8 of these
were detected by mediastinoscopy before thoracotomy, al-
lowing referral for induction therapy before pulmonary re-
section. Our aggressive prethoracotomy staging with rou-
tine FDG PET and mediastinoscopy identified unsuspected
distant metastases in 24 of 142 cases, pleural implants in 6
of 142 cases, mediastinal lymph node metastases requiring
a specialized approach for biopsy in 5 of 118 cases, and
mediastinal lymph node metastases that changed treatment
from primary surgery to combined modality therapy in 41 of
42 cases (34 detected by PET plus 7 additional detected by
mediastinoscopy). Altogether, there were 35 (24.6%) of 142
cases in which the FDG PET scan revealed disease that
would not have been found by conventional staging with
bronchoscopy and mediastinoscopy.
Improved accuracy in preoperative staging should pro-
vide an improvement in survival by two mechanisms. First,
selecting out patients with true stage IIIB and IV disease
from those with true stage I or II disease will improve the
prognosis of patients with the lower stages by stage migra-
tion (the Will Rogers phenomenon).33 Second, patients
whose disease is accurately downstaged are likely to have
more aggressive therapy, possible surgical resection, and
treatment with curative intent rather than palliative intent.
PET may also benefit the surgeon and patient by direct-
ing the lymph node sampling performed as part of a medi-
astinoscopy. With the advance notice of the presence of a
pathologic lymph node by PET, the surgeon will search
more aggressively for all nodes at that anatomic station.
This results in an improvement of the sensitivity of medi-
astinoscopy. Moreover, the presence of positive mediastinal
lymph node involvement on FDG PET may allow the tho-
racic surgeon to limit which lymph node stations need to be
examined. If PET predicts the presence of N3 disease, all
that is needed is to prove a single positive node on that side.
However, if PET predicts N2 disease only, one ipsilateral
positive node can be harvested but the contralateral side still
needs to be thoroughly sampled to exclude microscopic N3
lymph node disease, which PET could have missed.
Many surgeons commonly schedule mediastinoscopy
and thoracotomy as a combined procedure. With the high
positive predictive value of FDG PET in the mediastinum,
one does not need to plan the operating time to include a
thoracotomy when PET has predicted positive mediastinal
involvement. In instances in which mobilization of medias-
tinal tissues may be necessary as part of an extensive
resection (eg, carinal resection and reconstruction), one may
elect to stage the cancer by FDG PET only and plan to
perform the mediastinoscopy at the time of the planned
resection. This would avoid the development of scarring
after a staged mediastinoscopy, which would render the
eventual resection technically more difficult. FDG PET may
also be substituted for surgical staging in cases in which
surgical staging would be contraindicated or less safe. For
example, the aortopulmonary window of a patient with a left
upper lobe tumor is much more difficult to evaluate before
thoracotomy if the patient has had a left internal thoracic
artery cardiac graft. Other such scenarios in which a medi-
astinoscopy could be unsafe would include a patient who
has had a laryngectomy and one who has had a mediasti-
noscopy for a previous lung cancer workup and has a new
primary lesion. In these instances, reliance on FDG PET
staging may be necessary.
In our experience, the diagnostic accuracy of the PET-
enhanced clinical staging is high and far exceeds the accu-
racy of CT-only staging reported in the literature. Because
of its value in assessing the T status and anatomy of a tumor,
CT of the thorax remains necessary for initial NSCLC
staging. Because of the reported poor accuracy of CT in
staging the mediastinum, however, there may no longer be
a need for intravenous contrast administration if FDG PET
is to be performed as well.
The results for FDG PET accuracy reported in this study
are in keeping with those reported in the literature for
distant metastatic disease and mediastinal nodal evalua-
tion.18-20,32 Although many advocate the use of FDG PET in
place of surgical staging, we believe that the two are com-
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plementary and allow us to perform a more accurate overall
staging, to the benefit of the individual patient. PET has
previously been used primarily to screen for lymph node
spread and distant metastases, but it also provides localizing
information that allows directed and therefore more sensi-
tive surgical staging and refinement of patient selection for
curative resection.
We express our gratitude to Linda Wiens, BS, for her help in
organizing and checking the data for this article.
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Discussion
Dr John Mitchell (Stanford, Calif). Certainly it is hard to take
issue with the main premise of this study, that PET aids in the
staging of NSCLC. Since the mid 1990s we have all read several
reports documenting the superiority of PET scanning to CT in
identifying metastatic disease both within the mediastinum and at
distant sites. In this study of 144 patients with potentially operable
lung cancer, PET identified unsuspected distant metastatic disease
Vesselle et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 124, Number 3 517
G
TS
precluding resection in 16% of the patients and was able to
correctly differentiate the presence or absence of mediastinal
lymph node involvement approximately 90% of the time. Further,
use of PET scanning proved helpful in directing subsequent sur-
gical staging efforts and occasionally altered the method of surgi-
cal staging used in the patient evaluation. Realizing this, Vesselle
and colleagues point out that PET scanning should serve in a
complementary, rather than in a mutually exclusive, role with
other staging methods such as mediastinoscopy. However, in our
current era dominated by the ever-increasing pressure to contain
costs, it should be noted that a PET scan, with a price tag in the
thousands of dollars, is not an inexpensive test to order. In addi-
tion, access to a dedicated PET scanner, although improving, is
still not widespread. I am sure that there are still many thoracic
surgeons who are still sorting out the exact role that PET scanning
should have in the workup of their patients with NSCLC. With that
in mind, I have a couple of questions for Dr Vesselle.
First, although you touched on it somewhat in your presenta-
tion, I wonder whether you could comment further on how PET is
currently used at your institution in the evaluation of patients with
lung cancer. For example, do essentially all patients undergo PET
scanning, or is the test used at least somewhat selectively on the
basis of other imaging studies and the patient’s clinical presenta-
tion?
Dr Vesselle. FDG PET can serve several roles. The well-
established role that we are discussing now is that of staging, but
it can be used to restage, to look for sites of disease recurrence, and
to affect management. It can be used also to try to improve the
prognostic assessment in patients by looking at the level of uptake
in the primary tumor, which we did not discuss here. And it can be
used to assess response to therapy, and this is done by our che-
motherapy colleagues. With regard to using it as a primary staging
tool, our colleagues order it pretty much for all the cases that are
potentially resectable, because it helps in finding unsuspected
advanced disease and in localizing mediastinal disease. We make
strong efforts to schedule the cases in a timely fashion, so that the
surgeons can have the information provided to them without
delaying time to the operating room.
Dr Mitchell. Second, with the high diagnostic accuracy of PET
as you have noted in your study, do you believe that it is appro-
priate to omit mediastinoscopy or other further staging methods if
the PET scan is negative for the presence of mediastinal or distant
metastatic disease?
Dr Vesselle. This is a point of debate across the country. It
depends where one wants to operate in terms of accuracy. If one
wants a 98% or 99% accuracy in staging, one cannot omit the
surgical staging steps even with a well-performed FDG PET scan.
If one is willing to practice at a 90% or 85% accuracy level, I guess
these steps could be skipped. Because the chance for a cure for
these patients lies in resection, we do not want to deny a resection
to a patient because we have overread something. As you know, in
PET there are some cases of inflammatory nodes having uptake
that could be overread as N2 disease. At the same time, micro-
scopic disease is present, and we sometimes find it but in most
cases do not, and it is only found by harvesting the lymph nodes.
These patients with microscopic mediastinal disease are the ones
that are likely to respond the best to induction therapy. If we just
operate on them without detecting this microscopic focus of me-
diastinal disease, they will have tumor recurrence in the medias-
tinum. I think that the two modalities play complementary roles,
and we make every effort to stage these cases as well as possible.
Dr Mitchell. Your comments lead me to my third question,
which has to do with the limitations of PET scanning. The sensi-
tivity and specificity of PET are influenced by the inherent meta-
bolic activity of the tumor, the tumor volume, the metabolic
activity of the adjacent reactive cells, and the resolution of the PET
images. The limitations imposed by these factors were highlighted
in your article by the deliberate omission of tumors less than 1 cm
in size and by your admitted difficulty in accurately documenting
N1 disease. Could you comment further on the impact these
limitations had on your study, and on the use of PET scanning in
the evaluation of lung cancer in general?
Dr Vesselle. Yes, in this series we only reported on the patients
who had primary tumors greater than 1 cm in diameter, and a lot
of the tumors were small, between 1 and 2 or 1 and 3 cm. We had
a lot of T1 lesions. The reason why the small tumors were omitted
is not because we do not perform FDG PET on primary tumors that
are less than 1 cm in diameter but rather because this is part of a
larger, broader National Institutes of Health–funded trial looking at
the prognostic significance of the accumulation of FDG in the
primary tumor. To quantitate that properly in the PET scanner, you
cannot have a lesion that is too small, because if it is too small
relative to the resolution of the machine, there is a blurring that
takes place and the way we compute the standard uptake value of
the primary tumor gets really error prone as the lesions get very
small. This is why our series excluded the very small lesions, but
that has no bearing on the accuracy in the mediastinum. There is
no relationship that we have found between the size of the primary
and the accuracy of PET in the mediastinum at this point.
You wanted to know about the limitations of PET in general.
Detectability of a lesion, whether a primary tumor or a mediastinal
lymph node, by PET depends on two main factors. One is the
intrinsic characteristics of the scanner, its reconstructed resolution
from the processing you do of the data, and the other is the
metabolic activity of the cells that make up this lesion. For exam-
ple, although all NSCLCs in general are pretty metabolically
active, except for bronchoalveolar cell carcinomas, the cells that
make up a node will be hot, and it does not take much tissue for
us to be able to detect it. At the other end of the spectrum, a
slow-growing tumor such as prostate cancer, for example, does not
accumulate much of the FDG tracer, and it may take a centimeter
and a half worth of metastatic node before we can detect it by PET.
These two factors affect detectability of lesions, but they affect
NSCLC, with the exception of bronchoalveolar cell carcinoma
which is known to have low metabolic activity, a lot less than some
of the tumors with lower metabolic activity.
Dr Frederic Grannis (Long Beach, Calif). We are also inter-
ested in PET scan as a screening test. I am concerned about one of
your comments, that you consider mediastinoscopy to be the
criterion standard for detection of N2 metastases. I think that, for
example, the discussion from the Marie Lannelongue group, who
found 6 patients with N2 disease despite preoperative mediasti-
noscopy, would suggest that mediastinal lymph node dissection is
the criterion standard for the detection of N2 disease. Perhaps I
missed it, but did you do systematic mediastinal lymph node
dissection in this series?
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Dr Vesselle. No, I do not think so, but I think Dr Wood is the
best person to answer that question.
Dr Wood. You bring up a topic that you and I have debated at
other times. No, we do not do both sampling and lymph node
dissection. In the cases that have not had thorough mediastinos-
copy and lymph node sampling, we would do a mediastinal lymph
node dissection, but we do not do both. As you know, we are doing
a trial of that in ACOSOG (American College of Surgeons On-
cology Group) to see how much difference there is in mediastinal
lymph node dissection versus sampling, both in prognosis and in
identifying lymph nodes.
Dr Grannis. That is a good trial, and I think that it will show
that the criterion standard is dissection rather than mediastinos-
copy. To follow up on the size question, is immunohistochemistry
also going to be a criterion standard in the detection of N2 disease?
Dr Vesselle. You are talking about using immunohistochem-
istry on the sampled nodes, the same way as is done in breast
cancer?
Dr Grannis. That is correct.
Dr Vesselle. With regard to the dissection versus mediastinos-
copy issue, if you look at the role that PET played in this series in
guiding our surgical colleagues in finding the nodes that were
positive, it tremendously enhanced the mediastinoscopy yield. In
addition, it prompts the surgeon to find disease that would not be
reachable by mediastinoscopy, both pleural implants and nodal
stations not reachable by mediastinoscopy. I think that the two
modalities together really are synergistic and can improve our
surgical staging.
Dr Stephen Swisher (Houston Tex). Your article suggested
that PET was useful for detecting unsuspected systemic disease but
was not very good at identifying N1 or N2 nodes. There were 8
patients who had N2 nodes that were negative with PET but
positive at mediastinoscopy. Can you comment a little bit more
about these patients? Were they patients with microscopic foci of
disease that you could not see on CT?
Dr Vesselle. All these were patients who had no mediastinal
disease according to PET or CT, and in all cases there were
microscopic foci of disease in the mediastinal nodes. I can recall a
couple of patients. One of them had a right upper lobe tumor with
a right paratracheal station 4R lymph node, where the disease was
found as a really tiny focus at frozen section.
In addition, you mention the lack of detectability of N1 disease.
We believe that this is because N1 nodes are small, except when
they reach the hilum, and because they are located next to a hot
tumor we are not going to see them. These factors put together—
their small size and their presence next to a hot metabolic tumor—
make it difficult for us to see them on PET. Fortunately, it does not
change the overall management.
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